Ethnic inequity in the current approach to H. pylori testing and treatment

Making Education Easy

Authors:

Teng A et al.

March 20, 2025

Summary:

Māori and Pacific individuals have lower rates of H. pylori testing than Europeans, according to a data cohort study. Laboratory testing and pharmacy dispensing data were linked to the Northern region health user population dataset for the period 2015 to 2018. Compared with European individuals, H. pylori testing rates were lowest in Māori and Pacific individuals (odds ratios 0.69 and 0.81, respectively) and highest in Middle Eastern/Latin-American/African and Asian individuals (odds ratios 2.21 and 2.02, respectively). Treatment rates were lower in Pacific individuals and marginally lower in Māori compared with European individuals (hazard ratios 0.90 and 0.98, respectively). Māori and Pacific individuals were half as likely to be retested as European individuals.

Comment:

A reminder that concerted efforts to deliver equitable healthcare – in this case, testing for the antigen, treating with two weeks of antibiotic and other therapy and confirming resolution – is a critical step in addressing cancer inequities here in Aotearoa.

Reference: Helicobacter. 2025;30(1):e70005.

Independent commentary by Dr. Matire Hardwood

Dr Matire Harwood (Ngapuhi) has worked in Hauora Māori, primary health and rehabilitation settings as clinician and researcher since graduating from Auckland Medical School in 1994. She also holds positions on a number of boards, committees and advisory groups including the Health Research Council. Matire lives in Auckland with her whānau including partner Haunui and two young children Te Rangiura and Waimarie.

Research Review publications are intended for New Zealand health professionals.

Disclaimer: This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.